Ligand Pharmaceuticals Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Total Interest Expense	110.88	109.85	97.58
Net Interest Income	-110.88	-109.85	-97.58
Revenue Before Loan Losses	-110.88	-109.85	-97.58
Revenue	-110.88	-109.85	-97.58
Salaries & Employee Benefits	24	24	23
Cost of Services Provided	23.03	18.78	73.43
Other Operating Expenses	0	0	0
Total Operating Expenses	47.03	42.78	96.43
Operating Income	-157.91	-152.63	-194.02
Pretax Income	556.19	590.84	94.08
Income Tax Expense	179.31	170.03	9.31
Net Income	376.88	420.81	84.77
Net Income to Common	376.88	420.81	84.77
Net Income Growth	-	396.42%	-
Shares Outstanding (Basic)	9	9	4
Shares Outstanding (Diluted)	10	9	4
Shares Change (YoY)	-	152.18%	-
EPS (Basic)	41.40	46.24	23.49
EPS (Diluted)	41.40	46.24	23.49
EPS Growth	-	96.85%	-
Effective Tax Rate	32.24%	28.78%	9.90%

Source: S&P Global Market Intelligence. Financial Services template. Financial Sources.